Beyond Ozempic: the next decade of weight‑loss medicine
Think Ozempic is the end of the story? Prepare to be surprised. Drugs like Ozempic and Mounjaro have done one decisive thing: they proved obesity is treatable. They’ve shown that biology — not just willpower — drives appetite and body weight. Join us for a clear, evidence based conversation that cuts through the hype and delivers practical insight into how these drugs work in the brain and body, and why some people respond strongly while others do not. You’ll leave with a front row view of what comes after Ozempic – we can expect smarter combination therapies, fewer side effects, better muscle protection, and simpler ways to stay on track - and a realistic understanding of where the next decade of weight-loss medicine is headed.
Bio
Professor Garron Dodd is an internationally leading neuroscientist and Head of the Metabolic Neuroscience Laboratory at The University of Melbourne. He leads research programs focused on how the brain controls appetite, body weight, and blood sugar, and why people respond differently to weight loss and diabetes medicines. He has published in leading international scientific journals and received multiple awards for research impact. He is also a biotech founder and Chief Scientific Officer at Gallant Bio, translating discoveries into new therapies for obesity and type 2 diabetes. His work bridges cutting-edge neuroscience and real-world patient outcomes, with a focus on safer, more durable treatments.
Event
Wednesday 13 May, 6:00 pm @Quarterhouse, 693 Collins St, Docklands VIC 3008
Also speaking at this location at 8:00 pm is Associate Professor Michelle Peate
